Spotlight Poster Discussion 1 – Wednesday, December 8, 2021: 7:00 am – 8:30 am CT
   
  Endocrine Resistance
PD1-01 Estrogen therapy induces R-loop-dependent DNA damage that can be enhanced by PARP inhibition to improve response in ER+ breast cancer
Traphagen NA, Tau S, Jiang A, Wells JD, Hosford SR, Goen AE, Demidenko E. Geisel School of Medicine at Dartmouth College, Lebanon, NH; Dartmouth College, Hanover, NH.
PD1-02 Withdrawn
PD1-03 Estrogen receptor is a target of enzalutamide in ER+ breast cancer
Wei L, Yu J, Gao H, Zhang H, Nguyen T, Gu Y, Weinshilboum RM, Ingle JN, Wang L. Mayo Clinic, Rochester, MN.
PD1-04 Estrogen-mediated mechanisms in estrogen receptor-positive breast cancer at the single cell level
Mori H, Saeki K, Chang G, Wang J, Wu X, Hsu P-Y, Kanaya N, Somlo G, Nakamura M, Bild A, Chen S. City of Hope, Duarte, CA
PD1-05 Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer
Liu CC, Qin L, De Angelis C, Nanda S, Pereira R, Shea MJ, Nardone A, Jeselsohn R, Cohen O, Wagle N, Liu Z, Rimawi MF, Osborne CK, Schiff R, Fu X. Lester & Sue Smith Breast Center, Dan L Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, TX; Lester & Sue Smith Breast Center, Dan L Duncan Comprehensive Cancer Center and Medicine, Baylor College of Medicine, Department of Clinical Medicine and Surgery, University of Naples “Federico II”, Naples, Italy, Houston, TX; Lester & Sue Smith Breast Center, Dan L Duncan Comprehensive Cancer Center, Department of Molecular & Cellular Biology, Houston, TX; Department of Medical Oncology, Center for Functional Cancer Epigenetics, Harvard Medical School, Boston, MA; Department of Medical Oncology, Center for Cancer Precision Medicine, Dana-Farber Cancer Institute Harvard Medical School, Broad Institute of MIT and Harvard, Cambridge, Boston, MA; Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX; Lester & Sue Smith Breast Center, Dan L Duncan Comprehensive Cancer Center, Departments of Molecular & Cellular Biology, Department of Medicine, Baylor College of Medicine, Houston, TX.
PD1-06 Apobec mutagenesis is a pervasive feature of poor prognosis breast cancer associating with ESR1 wild type, endocrine resistant disease
Marra A, Gazzo A, Selenica P, Pei X, Gupta A, Pareja F, Curigliano G, Harris R, Riaz N, Reis-Filho JS, Chandarlapaty S. Memorial Sloan Kettering Cancer Center, New York, NY; Istituto Europeo di Oncologia IRCCS, University of Milano, MIlan, Italy; HHMI, Masonic Cancer Center, and Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN.
PD1-07 Mutant ESR1 receptors antagonize the tumor suppressor function of androgen receptors
Grimm SL, Gu G, Herzog SK, Gonzalez TL, Lin H, Beyer AR, Rechoum Y, Bawa-Khalfe T, Khan AF, Du L, Symmans WF, Kittler R, Coarfa C, Fuqua SAW. Baylor College of Medicine, Houston, TX; University of Houston, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX; UT Southwestern Medical Center, Dallas, TX.
PD1-08 Esr1 mutant breast cancers show elevated basal cytokeratins and immune activation
Li Z, Wu Y, Mcginn O, Bahreini A, Priedigkeit NM, Ding K, Onkar S, Sartorius CA, Miller L, Rosenzweig M, Wagle N, Richer JK, Muller WJ, Buluwela L, Ali S, Vignali DAA, Fang Y, Zhu L, Tseng GC, Gertz J, Atkinson JM, Lee AV, Oesterreich S. University of Pittsburgh, Pittsburgh, PA; University of Colorado Anschutz Medical Campus, Aurora, CO; Dana-Farber Cancer Institute, Boston, MA; McGill University, Montreal, QC, Canada; Imperial College London, London, United Kingdom; University of Utah, Salt Lake City, UT.
PD1-09 Constitutively active estrogen receptor mutants enhance breast cancer pathogenesis by co-opting progesterone receptor activity, which can be countered by Giredestrant
Liang J, Metcalfe C. Genentech, South San Francisco, CA.